Health Innovation Forum

WELCOME TO THE FRONT LINES OF CHANGE!

Health Innovation Forum is a multi-year program that aims to promote health care innovations within and beyond the McGill University Health Centre (MUHC). The MUHC's Institute for Strategic Analysis and Innovation (ISAI) has partnered with Parkhurst Publishing, a leading Canadian medical publishing company, to explore ideas, technologies and practices that can raise the bar on health system performance. The goal is to bring stakeholders in the health field together to explore approaches that respond to current needs and consider the full range of possibilities available for the future.

Key components include:

  • Round tables to discuss key developments in health care with front-line providers
  • Annual consensus-building conferences to examine fundamental issues
  • Publication of the Health Innovation Report to disseminate proceedings of events, commissioned papers and case studies

Health Innovation Forum is independently funded. Financial support is solicited from government and private sector stakeholders as well as through specific bequests to the MUHC Foundation.

Steering Committee

  • Bernard Lord, Scholar-in-residence, McGill University Health Centre's Institute for Strategic Analysis and Innovation; President and CEO, Canadian Wireless Telecommunications Association
  • The Honourable Arthur Porter, P.C. MD, Director General and CEO, McGill University Health Centre

  • Susan Usher, Director, Health Policy Division, Parkhurst Publishing Ltd.
  • Harris Poulis, General Counsel and Director of Legal Affairs, McGill University Health Centre 

  • Helen Antoniou, Associate Director General, Public Affairs and Strategic Planning, McGill University Health Centre
  • Christos Kritsidimas, Special Advisor, Office of the Director General and CEO, McGill University Health Centre
  • Robert Babczak, Special Projects Coordinator, Executive Office, McGill University Health Centre

See McGill University Health Centre press release.

About the McGill University Health Centre and ISAI

The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. The MUHC is a merger of six teaching hospitals affiliated with the Faculty of Medicine at McGill University — the Montreal Children's, Montreal General, Royal Victoria, and Montreal Neurological hospitals, as well as the Montreal Chest Institute and the Lachine General Hospital. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field, and to contribute to the development of new knowledge.

ISAI was created to allow the MUHC to play a leadership role in health policy development. Its first two programs are a scholar-in-residence program and the Health Innovation Forum. Mr. Bernard Lord, former premier of New Brunswick joined ISAI as first scholar-in-residence in 2007. The Institute aims to assume a significant role in framing and evaluating public policy, and help clarify the ground rules on which health care will evolve in the coming years.

About Parkhurst

Parkhurst Publishing is a Montreal-based medical publisher with a 25-year history producing high-quality, broadly read medical magazines. Their three physician publications, Doctor’s Review, Parkhurst Exchange and National Review of Medicine, reach over 40,000 doctors across the country. A fourth, Oncology Exchange, is published for cancer specialists. Parkhurst also produces a range of publication for patients living with demanding diseases. Parkhurst's Health Policy Division has been involved for the past 12 years in bringing stakeholder together to examine aspects of Canada’s health care system for academic and government organizations as well as healthcare companies.

MUHC-ISAI Partners’ Advisory Council

MUHC-ISAI activities are supported by a select group of companies, which are developing some of the programmes and products that will help shape the future of health care.

 

GOLD PARTNERS

 

Founded more than 100 years ago, McKesson Canada is the leading provider of logistics as well as information products and services within the Canadian health care marketplace. McKesson Canada carries more than 35,000 products, in 17 distribution centres, and provides logistics and distribution for more than 800 manufacturers — delivering their products to 6,300 retail pharmacies, 1,350 hospitals, long-term care centres, clinics and institutions throughout Canada. Beyond pharmaceutical distribution, McKesson Canada has provided automation services for 2,500 retail pharmacies; and is also active in hospital automation solutions, dispensing more than 100 million doses each year. Many hospitals across Canada utilize one or more Mckesson software solutions to support their clinical and administrative processes. The company also provides a full range of therapy and disease management services to Canadian manufacturers and health care providers, contributing to the quality and safety of care for Canadians.

For more information visit www.mckesson.ca.

 

From its approach to clinical trials for new drug therapies, to industry partnerships and community involvement, Roche Canada is a leader in providing pharmaceutical and diagnostic solutions that make a profound difference in people’s lives. The company’s innovative approach improves the effectiveness and efficiency of the healthcare system in the diagnosis, treatment and management of acute and long-term disease.

Roche Canada employs approximately 900 people across the country, with its pharmaceuticals head office located in Mississauga, Ontario and diagnostics division based in Laval , Quebec. The company serves a broad base of healthcare facilities and practitioners across the country, working in partnership with them to ensure that the diagnostics and therapies it delivers meet the medial needs of today and of the future.

For more information, visit www.rochecanada.com.

 

SILVER PARTNERS

 

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. GE’s broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help its customers to deliver better care to more people around the world at a lower cost. In addition, GE partners with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable health care systems. GE’s “healthymagination” vision for the future sees continual innovation focused on reducing costs, increasing access and improving the quality and efficiency of health care around the world.

For more information about GE Healthcare, visit the website at www.gehealthcare.com.

 

Today’s Merck is working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products. In Canada, Merck markets over 530 pharmaceutical, consumer and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines, women’s health and sun care, and is focused on expanding offerings in other areas, including virology, oncology and diabetes.

Merck is one of the top R&D investors in Canada, with an investment of $78.6 million in 2010. Merck has a large manufacturing facility in Québec dedicated to the annual production of some 35 million units of its various brands, including Claritin® and Aerius®. Based in Montréal, Québec, Merck employs over 1400 people across Canada. For more information about our operations in Canada, visit www.merck.ca.

 

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi is represented in Canada by the pharmaceutical company sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines company Sanofi Pasteur Limited, based in Toronto, Ontario. Together they employ more than 2,000 people across the country. With combined R&D investments of $159.2 million in 2010, they are leaders in Canada’s biopharmaceutical sector, a critical knowledge-based industry that generates jobs, business and opportunity throughout the country.

 

Pfizer Inc. is the world’s leading pharmaceutical company. Pfizer invests more than $7 billion annually to discover and develop life-saving and life-enhancing medications for humans and animals. Pfizer Canada is a leader in Canadian healthcare research, investing more than $137 million in research and development activities, contributions and partnerships in 2008. The company has invested more than $1 billion in R&D since 2000. Pfizer Canada is also working to strengthen connections between academia and the commercial world to fast-track the commercialization of promising research. In the past year, it has invested over $15 million in four public-private partnership projects arising out of the new Centres of Excellence for Commercialization and Research. Pfizer Canada’s commitment to helping Canadians live happier, healthier and longer lives extends beyond medication. To learn more about Pfizer Canada’s more than medication philosophy and programs, visit www.morethanmedication.ca.